Researchers at the University of Florida College of Veterinary Medicine and the UF Health Cancer Center have identified a crucial link between a gene mutation and immune system signaling in canine hemangiosarcoma, a discovery that could lead to better treatments for both dogs and humans with similar cancers.
Most patients who enroll in the Lung-MAP precision medicine trial in non-small cell lung cancer can now be matched to a targeted investigational treatment based on the results of their prior genomic testing, without needing to submit new tumor or blood samples.
